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Abstract
Background: Poor growth and under-nutrition are common in children with sickle cell disease (SCD). This review
summarises evidence of nutritional status in children with SCD in relation to anthropometric status, disease
severity, body composition, energy metabolism, micronutrient deficiency and endocrine dysfunction.
Methods: A literature search was conducted on the Medline/PUBMED, SCOPUS, SciELO and LILACS databases
to July 2007 using the keywords sickle cell combined with nutrition, anthropometry, growth, height and weight,
body mass index, and specific named micronutrients.
Results: Forty-six studies (26 cross-sectional and 20 longitudinal) were included in the final anthropometric
analysis. Fourteen of the longitudinal studies were conducted in North America, the Caribbean or Europe,
representing 78.8% (2086/2645) of patients. Most studies were observational with wide variations in sample size
and selection of reference growth data, which limited comparability. There was a paucity of studies from Africa and
the Arabian Peninsula, highlighting a large knowledge gap for low-resource settings. There was a consistent pattern
of growth failure among affected children from all geographic areas, with good evidence linking growth failure to
endocrine dysfunction, metabolic derangement and specific nutrient deficiencies.
Conclusions: The monitoring of growth and nutritional status in children with SCD is an essential requirement for
comprehensive care, facilitating early diagnosis of growth failure and nutritional intervention. Randomised
controlled trials are necessary to assess the potential benefits of nutritional interventions in relation to growth,
nutritional status and the pathophysiology of the disease.
Introduction
It is generally accepted that homozygous
sickle cell disease (SS) impairs physical
growth during childhood and early adoles-
cence and that affected children are lighter
and shorter than healthy counterparts.
Growth retardation in sickle cell disease
(SCD) is complex and multiple factors are
likely to contribute, such as the haematolo-
gical and cardiovascular state, social factors,
endocrine function and metabolic and
nutritional status.1 Growth rate is inversely
related to the degree of anaemia and is likely
to be associated with deficiency of specific
nutrients as well as low nutrient intake,
decreased absorption and increased losses or
utilisation.2,3
For example, the prevalence of under-
weight in American children with SCD was
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41% for moderate and 25% for severe
under-nutrition4 with a prevalence of wast-
ing of 11%.5 Stunting was reported in 44%
of Ghanaian children and adolescents and
almost all those with SS were underweight,
irrespective of height.6
Although growth failure and under-
nutrition are common, the underlying
mechanisms have not been well studied
and the precise role of intrinsic or extrinsic
factors is unclear in relation to inadequate
food intake or increased demands associated
with higher energy expenditure and require-
ments. External and internal factors are
likely to act together to a different degree
against a variable genetic, environmental
and socio-economic background. The aim
of this review is to summarise the evidence
related to poor growth and under-nutrition
in children with SCD with regard to
anthropometric status, disease severity,
body composition and metabolism, micro-
nutrient deficiency and endocrine dysfunc-
tion. An important aspect of these analyses
is determining whether phenotype, nutri-
tional deficits or anaemia individually con-
tribute to growth restriction, or whether it is
a combination of these factors which is
important.
Methods
A literature search using the Medline/
PUBMED, SCOPUS, SciELO and
LILACS electronic databases for studies
published up to July 2007 was conducted.
The search terms sickle cell combined with
nutrition, anthropometry, growth retarda-
tion, height and weight, body mass index
(BMI) and specific micronutrients (zinc,
iron, vitamins A, B group, C, D, E and
folate) were used. Additional articles were
identified by checking reference lists of
retrieved articles. From a total of 423
published studies, 42 with relevant data
(25 cross-sectional and 17 longitudinal)
were selected. In addition, data were made
available from unpublished studies (one
cross-sectional and three longitudinal).
The following data were extracted from
these studies: age, disease severity, clinical
presentation and growth parameters, use of
blood transfusion, therapeutic interventions,
micronutrient status and other nutritional
and endocrine assessments, and haemoglo-
bin genotype. The resulting data were
tabulated by geographical location, age,
anthropometric characteristics and types of
controls.
There are four major genotypes within the
definition of SCD: homozygous sickle cell
(SS) disease, sickle haemoglobin C (SC)
disease, sickle cell bz thalassaemia (S bz
thalassaemia) and sickle cell b0 thalassaemia
(S b0 thalassaemia).7 The internationally
accepted definition of SCD, two b-globin
gene variants at least one of which is the
sickle cell gene, is used and the gene variant
for the four common genotypes are indi-
cated when known. In this review, the term
‘sickle cell anaemia’ is used synonymously
only for homozygous SS disease, and the
majority of studies reviewed relate to this
genotype.
Results
Nutritional status and disease severity
Inadequate intake can result from anorexia,
a prominent symptom in affected children
even in the absence of demonstrable infec-
tion, and it often precedes a painful crisis by
days or weeks.8 At the time of hospital
admission, energy intake during acute illness
is decreased by as much as 44% of the
recommended daily amount (RDA) (SD
9%); during follow-up, intake is closer to
90% of RDA.9 Dietary intakes can be
reduced markedly prior to admission and
remain sub-optimal for weeks.10 In a
Jamaican study, no significant relationship
was demonstrated between haemoglobin
concentration, reticulocyte count or irrever-
sibly sickled cells and anthropometric
measurements. Correlation with disease
severity, measured by the number of
166 A.-W. M. Al-Saqladi et al.
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hospital admissions, showed no significant
association with growth parameters,
although a trend towards lower mean weight
was found in patients who were admitted
more often.11 In pre-pubertal Jamaican
children, levels of haemoglobin (Hb) and
fetal haemoglobin (Hb F) decreased with an
increasing number of hospitalisations of
both sexes, although levels were positively
associated with height and weight only in
males.12
Vaso-occlusive crises and episodes of
infection could increase energy expendi-
ture.13 A strong association between C-
reactive protein and resting energy expendi-
ture has been described, which might
indicate a link between inflammation and a
hyper-metabolic state in SCD.14 Increased
resting energy expenditure (REE) might
relate to erythroid hyperactivity and accel-
erated red cell turnover owing to the short
life span of sickled red blood cells. Low Hb
levels and chronic anaemia are associated
with hyperdynamic circulation and dete-
rioration of cardiopulmonary function. This
increases workload and, consequently, the
demand for energy and nutrients.
There is evidence that nutrient supple-
mentation can reduce clinical illness.
Supplements given by the nasogastric route
to SCD children with growth retardation
(weight and height ,5th centile) led to a
rapid and sustained increase in growth and a
reduction of pain crises and episodes of
infection.15 The authors found no lipid
malabsorption and a normal histological
appearance of the intestinal mucosa and
submucosa and concluded that inadequate
energy intake was responsible for the growth
retardation.
Other therapeutic measures to reduce
disease severity or complications (i.e. blood
transfusion, splenectomy and hydroxyurea)
might lead to improved nutritional status
and growth. Children in the Stroke
Prevention Trial in Sickle Cell Anaemia
(STOP) who received transfusion
regularly over a 2-year period demonstrated
significant improvement in height, weight
and BMI, with growth Z-scores approaching
normal.16 Those with homozygous SCD
showed a significant reduction in whole
body protein turnover (from 8.9 g/kg/d to
6 g/kg/d) after splenectomy, thereby con-
tributing to positive energy balance17 and
acceleration in linear growth.18 Therapy
with hydroxyurea has been reported to
decrease REE in treated SS children,
suggesting that it might curtail a hyper-
metabolic state and offer clinically impor-
tant secondary benefit.19 In the
Hydroxyurea Safety and Organ Toxicity
(HUSOFT) extension study, improved
growth rates were demonstrated in SS
children treated with hydroxyurea. Their
increased weight and height resulted in a
growth pattern similar to that of children
with Hb S bz thalassaemia or healthy
controls.20 Studies related to growth, spe-
cific micronutrients and disease severity are
considered in later sections of this review.
Growth studies
Studies reporting growth of patients with
SCD are summarised in Tables 1–6. Adult
patients are often described as slender with
low weight, relatively tall with long extre-
mities, short trunk, narrow shoulders and
hips, with a deep chest and increased
anterior-posterior diameter. Many of these
changes were found to be less pronounced
and inconsistent in children, and some
investigators considered this appearance in
SCD to be an exaggeration of the normal
characteristics of Africans.21Affected chil-
dren were reported to have poor nutrition
and their weight was consistently below the
median reference values.
North American studies (Table 1). An early
study of the growth of 48 American black
children with sickle cell anaemia (aged 2–13
yrs) reported that the majority were thin
with low weight and height. There was no
correlation between growth parameters and
the clinical course, arterial oxygen satura-
tion or family childhood weight patterns.22
Growth in SCD 167
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Jimenez et al.23 compared 20 SS females
with 774 race-matched controls (11–40 yrs).
There was delay in onset of menarche and
age at first pregnancy, decreased fertility and
an increased incidence of abortion and
premature delivery. In a separate group of
38 cases in the same study, a low weight,
height and upper-to-lower segments ratio
was observed compared with 89 control
black children of the same age. McCormack
et al.24 reported the growth of 46 American
black children and adolescents with SS
disease. In all age groups (1–17 yrs), they
had lower mean height, weight, mid-upper-
arm circumference (MUAC), thinner body
build and delayed skeletal maturation com-
pared with controls.
Height and weight deficit probably occurs
early in life. Booker et al.25 reported weight
deceleration starting at about 4–6 months of
age, coinciding with the onset of crises and
infections and continuing during the 1st 2
years of life. Age-related growth deficit will
be difficult to demonstrate accurately with
longitudinal birth cohort studies until neo-
natal screening for haemoglobinopathies
becomes more widely available. In a pro-
spective study of 14 Canadian neonates with
Hb SS, Kramer et al.26 found no significant
differences in birthweight or length com-
pared with controls, indicating an absence
of disease effect on fetal growth.26 During
follow-up of ten pairs of these children to 3–
6 years of age, a growth deficit was noted
from about 6 months of age.
In a 3-year longitudinal study which
included 26 boys and 29 girls with sickle
cell anaemia (13–18 yrs), there was sub-
normal weight and height and significant
retardation in growth velocity. Skeletal
maturation and sexual development were
significantly retarded but, with adjustment
for bone age and Tanner staging, sexual
development was considered appropriate for
bone age.27
A larger, cross-sectional, multi-centre
study was undertaken which included 2115
cases with different sickle cell syndromes
(1404 SS and the remainder with SC
disease, S bz thalassaemia or S b0 thalas-
saemia).28 The mean height and weight of
affected subjects were significantly below
reference values and the difference became
apparent after 7 years of age. Children with
Hb SS and S b0 thalassaemia were consis-
tently smaller and less sexually mature than
those with SC disease and S bz thalassae-
mia. Sexual maturation followed the pattern
of height and weight, and time of menarche
correlated well with weight and age.
Height and weight impairment at all ages
and in both sexes compared with published
growth reference values was reported in a
cohort study of 133 SS American children
followed from early childhood to adoles-
cence.29 The deficit in height and weight
had commenced by 2 years, increased with
age and was more pronounced in males of
all ages. Growth velocity curves for 13
adolescents showed significant delay of
pubertal growth. The mean difference in
weight and height in a study of 30 SS
children (8–19 yrs) paired with matched
controls of the same age, sex, race and
socio-economic status was a deficit of 12 kg
weight and 8 cm height, with a 0.75-year
delay in sexual maturation based on Tanner
staging.30 No difference in body image was
detected between cases and controls. A
recent longitudinal study of 148 SS children
showed that the growth deficit for one or
more indicators occurred in 84% of sub-
jects, and 26%, 22% and 24% were ,5th
reference centile for weight, height and
BMI, respectively. Puberty was delayed by
1–2 years. Disease severity assessed by
hospitalisation, blood transfusion and hae-
matological status was associated with long-
itudinal growth in females but not in
males.31 The cause for this sex difference
is unclear, but other studies have reported
similar findings and related it to differences
in the level of Hb, Hb F, energy intake and
hormonal changes, especially at the time of
puberty.12,29,32–34
Jamaican studies (Table 2). Ashcroft et al.35
studied growth in 99 adolescents (12–21
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yrs) with sickle cell anaemia who had low
mean weight and delayed skeletal age (based
on hand radiography) compared with nor-
mal and sickle cell-trait (AS) controls.
Height differences were variable: younger
patients were shorter whereas older ones
were as tall as controls.
Lowry et al.11 studied 99 SS children (2–13
yrs) and reported a mean value for weight
below Jamaican reference values for both
sexes, although little difference was observed
in height. In their follow-up study of 82 SS
children (2–21 yrs), Ashcroft & Serjeant36
reported that, while the weight deficit per-
sisted, height continued to increase and final
height was equal to or better than that of
normal subjects. This was presumed to be a
result of delayed epiphysial fusion with final
height determined by the degree of delay. In a
further study, the anthropometric measure-
ments of 64 SS children showed a significant
deficit in mean weight, height and MUAC by
4–6 years.37 Limbs were shorter than those of
controls, although the sitting–standing height
ratio was normal.
A longitudinal study of children with SS
and SC disease, followed from birth to 9
years of age and compared with normal AA
controls, showed no birthweight differences
for either gender; the weight deficit in the SS
children commenced before the end of the
1st year of life.32 The deficit appeared to be
relatively more marked in girls and a similar
trend was observed for height. Weight and
height velocity deficits increased after the
age of 7 years and there was a bone age
difference by 5 years with a retardation of
0.4 years in boys and 0.6 years in girls. By
the age of 8, this had increased to 1 and 1.3
years in boys and girls, respectively.
Children with SC disease showed no growth
deficit.32 The time of the growth spurt was
delayed by 1.4% years in 44 homozygous
SCD adolescents and normal height was
attained by 17.9 years.38
Disease-specific growth reference curves
for children with homozygous SCD were
produced using data obtained from a cohort
of 315 children aged 0–18 years by the LMS
(lambda-mu-sigma) method which is used to
normalise and smooth growth centile
curves.39 Values from the LMS smoothed
curves were used to generate centiles
expressed at selected ages as standard devia-
tion scores (Z-scores) using NCHS growth
reference standards. Mean height and weight
at birth in both sexes were similar to reference
values but fell away subsequently before
catching up at around 15 years in girls and
18 years in boys.39 The applicability of this
reference curve to countries other than
Jamaica needs to be evaluated.
Latin-American studies (Table 3). In a study
of 14 SCD Brazilian children (6 mths–12
yrs), all had growth retardation and weight
and height were ,10th centile of the NCHS
reference.40 Serum zinc levels were low but
not correlated with growth deficit. Low
serum zinc was also reported in 18 SS
Venezuelan children.41 In 34 Brazilian SCD
patients (6–20 yrs), low weight-for-age but
not height-for-age was significantly asso-
ciated with delayed menarche and bone
age.42 Compared with pubertal matched
controls, no difference in levels of serum-
follicle stimulating hormone (FSH) or lutei-
nising hormone (LH) before or after LH–
FSH stimulation tests was detected.
Another Brazilian study of 86 SS patients
under 20 years of age reported weight and
height ,10th centile in 40% and 31% of
cases, respectively, and the weight deficit
persisted after puberty.43 In a follow-up of
34 SS Brazilian patients (0–18 yrs),
impaired growth velocity increased with
age, and reduced weight and height were
associated with low serum zinc and ferritin
levels.44 Family height channels were eval-
uated in 76 SCD children (9 mths–20 yrs)
from Brazil and corrected for parental
height. Overall, allowing for mid-parental
height, 41% were below the expected centile
value and did not attain normal height and
weight in adulthood.45 Although the max-
imum growth velocity occurred later than
normal owing to delayed puberty, the
magnitude of this spurt did not compensate
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for the early growth delay and final size
remained below normal. This contrasts with
some Jamaican studies36,38 and the differ-
ence might relate to genetic factors govern-
ing parental stature. In another group of 73
SS Brazilian children using NCHS reference
values, comparison of Z-scores for height
or weight-for-age and weight-for-height
showed that almost 10% of cases were
under-nourished (Z-score (2).33 After 1
year of follow-up, the weight- and height-
for-age deficits became significant and were
greater in boys. Conversely, Gonza´les et al.46
reported no significant difference in weight,
height and bone age in 110 SCD Cuban
children less than 17 years of age (74 SS
cases) compared with Cuban standards.
African studies (Table 4). Anthropometric
values for weight, height and mid-arm cir-
cumference of 719 SS Nigerian children were
reported to be ,50th centile of the Harvard
standards, the most marked deficit being
weight-for-age.47 Compared with healthy
Nigerian children, 85 SS children (9 mths–
17 yrs) showed weight and height below and
around the 3rd centile.48 In a study of 20
adults, anthropometric measurements were
lower in males but not in females.34 This was
associated with lower daily energy and macro-
nutrient intake by males than by controls. A
further study of 177 Nigerian children and
adolescents ( 1–18 yrs) with SCD reported
anthropometric values close to the 3rd centile
of reference values with no significant differ-
ence between cases and controls except at the
age of 18 years.49 A high prevalence (21%) of
maxillary prognathism and malocclusion was
reported among cases. However cases and
controls were mostly from a lower socio-
economic class, which might explain the lack
of significant differences in anthropometric
measurements between the groups.
Evaluation of body composition in 91
Congolese SS children (8–14 yrs) showed
significantly lower mean weight, height, BMI,
lean body mass and percentage of body
fat than in age-matched AA controls.
Alteration in body composition correlated to
the frequency of painful and anaemic crises.50
Delayed sexual maturation was observed in 72
homozygous SCD Congolese girls with delay
in the age at thelarche and menarche.
Menarche had not occurred by 14–18 years
in 71% of these cases compared with 10% of
controls.51 In a study from Gabon, 27% of
131 children with sickle cell anaemia (,18
yrs) had weights and heights ,22 SD
compared with African multi-ethnic reference
values.52 In Zambian children with sickle cell
anaemia, 60% and 53% were,5th centile for
weight and height, respectively, compared
with NCHS reference values.53
Middle East and India (Table 5). In a group
of transfusion-dependent Egyptian children
which included 110 cases of SCD, height
was ,22 SD in 27%, and 51% showed a
growth velocity ,21 SD. MUAC, triceps
skinfold thickness and BMI were signifi-
cantly lower than in controls, and linear
growth was delayed increasingly with age.54
Despite regular blood transfusion, onset of
puberty and sexual maturation were
delayed. Mean adult height was not attained
in 96% of 75 SCD male Iraqi patients who
were all 18 yrs of age, and 45% had delayed
sexual maturation.55 In 97 Omani children
(90 SS, 7 S b0 thalassaemia), weights in
68% were below the NCHS 5th centile
compared with 28% of age- and sex-
matched non-sicklers. When these data were
plotted against Jamaican sickle cell reference
values, 14% were ,3rd centile.56
Nutritional status in 102 SS Yemeni chil-
dren (6 mths to 15 yrs) was compared with
NCHS reference values. Growth deficit
(,22 Z-score) occurred in 72% based on
weight-for-height, in 55% based on height-
for-age and in 52% based on BMI (A.-W.
M. Al-Saqladi, unpublished data). In Saudi
Arabian children, there was no significant
difference in serial height and weight mea-
surements during the 1st 2 years of life in
either 14 male or 7 female patients com-
pared with matched controls from the east-
ern region of the country where the disease
is generally mild.57
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A study of 58 SS Indian children (2–14
yrs) reported significantly lower anthropo-
metric values for all indicators except the
upper/lower segment ratio compared with
normal age- and sex-matched controls.
Males and females were affected equally.58
European studies (Table 6). Moderate
growth delay was reported in 76 white
Sicilian children (1–17 yrs) with SCD.59
Weight and height were ,3rd centile of
reference values for white British children in
16% and 10.5%, respectively. The majority
had Benin haplotypes and showed no
growth differences compared with b-S
thalassaemia.
Mann60 reported 61 SS patients (3 mths
to 19 yrs) in England whose heights were
.2 SD below the mean Caucasian reference
value. The varied clinical manifestations
compared with reports from Jamaica or
North America led the author to conclude
that variation depended on many factors
including climate, endemic infection and
the general standard of nutrition and med-
ical care. Comparison of a further 56 SCD
British children with controls of Caucasian
(CC) or African/Caribbean (AC) origin
showed that they were taller but that their
weight and BMI were similar to CC con-
trols.61 Weight and BMI were significantly
lower than in AC controls but there was no
difference in height. Three unpublished
longitudinal studies were identified, preli-
minary data for which are summarised in
Table 6.
Summary. Growth retardation in children
with SCD is well established and SS
individuals are affected more severely than
children with other sickle cell haemoglobi-
nopathies. Growth failure occurs among
affected children in all geographical areas,
although the relevance and severity vary
with location and are most marked in low-
resource settings. Children with SCD have
normal birthweight and length, with growth
restriction commencing between 6 months
and 2 years. European children show better
growth than those elsewhere, probably
indicating better nutrition and quality of
care.
Body composition and energy metabolism
To understand the nutritional needs and
interventions required in children with
SCD, it is important to know the nature
and magnitude of the body compositional
deficits. A study of body composition in 36
Afro-American children with homozygous
SCD found significantly lower Z-scores for
weight, height, MUAC or upper arm fat and
muscle in affected children.62 A marked
reduction in fat-free mass (FFM) and body
fat indicated a global deficit of energy and
protein stores, suggesting that nutritional
needs were not being met.
Whole body protein turnover and resting
metabolic rates are higher in SS adults than
in AA controls. Protein turnover is an
energy-consuming process which could
account for increased energy expenditure.
Patients with SCD disease could therefore
be in a hyper-metabolic state, requiring
higher energy and protein intake to maintain
normal function.63 The resting metabolic
rate was found to be 19% higher in
homozygous SCD than in AA controls and
the difference was not related to the size of
lean body mass.64 When lean body mass or
FFM are taken into account, REE per kg of
FFM was 25–50% higher than normal.65
The composition and tissue-specific meta-
bolic rates comprising lean body mass/FFM
in SS subjects is likely to differ from those of
AA controls.64,65 Whole body protein break-
down and synthesis was increased by 32%
and 38%, respectively,66 and the energy cost
of increased protein synthesis was estimated
to be approximately 50% of increased
REE.67 This increased energy expenditure
and protein turnover could result from
hyperactivity of bone marrow during ery-
throblastosis secondary to haemolysis and
red cell destruction. The imbalance between
energy requirements and expenditure
would lead to a marginal nutritional state,
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contributing to growth impairment that
might potentially be corrected by energy
supplements. To adapt to this state, there
might be a reduction in physical activity. To
compensate for their high resting metabolic
rate, patients with SCD might try to
economise on energy by decreasing physical
activity. This mechanism cannot compen-
sate for long-term energy deficiency or the
imbalance between metabolic demands and
energy consumption which ultimately lead
to growth impairment.68,69
Pre-albumin, used to assess nutritional
status, has been reported to be low in
SCD.70 Urinary loss of amino acids might
also contribute to slow growth. One study
reported no differences in the concentration
of serum total proteins between SCD
children and controls, but serum levels of
pre-albumin, all essential and most non-
essential amino acids were significantly
lower with higher urinary concentration of
amino acids.71
Changes in carbohydrate and lipid meta-
bolism in SCD have been evaluated by
measurement of whole body glucose and
lipid metabolism in adults. Results showed
that these were not significantly affected and
the plasma concentration of insulin, gluca-
gon, cortisol, nor-epinephrine and epi-
nephrine were similar in patients and
controls.66 Serum levels of total phospholi-
pids were within the normal range in
children with sickle cell anaemia, while
docosahexaenoic acid (DHA), eicosapen-
taenoic acid (EPA), total polyunsaturated
fatty acids (PUFA)72 and cholesterol73,74
were decreased. With an imbalance between
n-3 and n-6 long-chain PUFA in erythro-
cytes and plasma, alterations in the lipid
layers of the red-cell wall might be ante-
cedent to red-cell asymmetry, adhesion and
aggregation and precede vaso-occlusion.75
Plasma concentration of type I procolla-
gen carboxy-terminal propeptide (PICP),
the major collagen produced by osteoblasts
during bone formation, and urinary excre-
tion of urinary pyridinoline cross-links
(PYD) formed from type I collagen during
bone resorption have been used as indirect
measures of bone turnover. In adolescents
with sickle cell anaemia compared with AA
controls, these bone marrow resorption and
formation markers were increased, suggest-
ing increased protein formation and break-
down in bone marrow. This could relate to
elevation in whole body protein turnover
and REE in SS patients.76 Bone mineral
density, assessed by dual-energy X-ray in 25
children and adolescents (9–19 yrs) with
severe sickle cell anaemia, was found to be
reduced in 64%. This was associated with
deficient calcium intake and low serum
levels of vitamin D.77
Glutamine is the most abundant amino
acid in humans and is the preferred fuel for
rapidly dividing cells such as reticulocytes.
Its use in children with sickle cell anaemia
was reported to be 47% higher than in
controls and to be associated with a 19%
increase in REE and a 66% increase in
cardiac output. These changes might be
attributable to increased haemoglobin
synthesis and cardiac workload.78
Attempts to lower REE using oral gluta-
mine led to a reduction of about 6%, which
was greater in children who were under-
weight. Improved BMI and body fat
components indicated that lowering REE
by increasing energy intake and glutamine
administration could be an effective way of
promoting growth in children and adoles-
cents with SCD.79
Metabolic studies suggest that children
with SCD have a higher resting metabolic
rate and REE, which increases their meta-
bolic demands and requirements for protein
and energy. Factors which contribute to
higher REE include increases in protein
turnover, erythropoieses, cardiac workload
and underlying inflammation. The child’s
body composition, nutritional status and
clinical condition all influence metabolic
rate and nutritional requirements and these
need to be well defined in order to under-
stand the potential role of nutritional inter-
ventions for improving health.
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Endocrine dysfunction and growth retardation
In children with SCD, delayed sexual
maturation is frequently associated with
growth retardation.31 Although its contribu-
tion to growth deficit is unclear, it might not
have a primary endocrine cause.3 Deter-
mination of gonadotropin concentrations in
40 children with sickle cell anaemia (5–16
yrs) showed a significant increase in LH in
children aged 5–10 years and normal levels
in older children. The levels of LH and FSH
were higher in patients than in controls at
the same stage of development of secondary
sexual characteristics. This suggested a
variation in the rate of maturation of the
hypothalamic–pituitary gonadotropin axis
rather than gonadal hypofunction.80
Evaluation of gonadal function in adults
with SCD showed that serum testosterone,
dihydrotestosterone (DHT) and androste-
nedione levels were low.81 High LH and
FSH levels were observed before and after
stimulation with gonadotropin-releasing
hormone, which correlated with testicular
size and retarded secondary sexual charac-
teristics. This suggests that gonadal hypo-
function is not related to pituitary failure but
is consistent with primary gonadal failure.
This study also reported reduced erythro-
cyte and hair zinc concentrations which
significantly correlated with androgen sta-
tus. The influence of chronic zinc deficiency
on gonadal growth and function was con-
sidered important. Evaluation of the
hypothalamic–pituitary axis by administra-
tion of gonadotropin-releasing hormone–
thyrotropin-releasing hormones has
demonstrated higher concentrations of LH,
FSH, thyroid stimulatuig hormone and
prolactin hormones in male patients than
in controls, which suggests a primary gona-
dal failure in adults82 and in children with
extreme retardation of puberty.83
There is also some evidence for partial
hypothalamic hypogonadism.84 Signi-
ficantly reduced concentrations of testoster-
one, LH and FSH in adults with SS disease
supports gonadal hypofunction secondary to
hypopituitarism.85 Delayed testicular devel-
opment has been demonstrated in male
sicklers, predominantly in boys aged 10–15
years who had delayed puberty but attained
normal sexual maturation.43
In a longitudinal study of 55 American
children with SCD and reduced weight,
height and retarded bone age, there was
delayed sexual maturation which, though
prolonged, progressed in an orderly man-
ner.27 The average age of menarche in
affected girls was 15.4 vs 12.6 years in
normal girls. In the majority of these
children, hormonal assays indicated an
intact pituitary–hypothalamic axis with
appropriate adrenal and gonadal responses
and only patients with marked delay in
sexual maturation showed lower gonadal
hormones. Age at menarche in Jamaican
girls was delayed by 2.4 years in 99 cases
with homozygous SS disease, and by 0.5
years in 69 SC cases compared with a mean
age of 13 years in AA controls.86 Weight was
found to be the dominant determining
factor for age at menarche in cases and
controls. The authors considered their find-
ings favoured sub-optimal nutrition as a
cause of pubertal delay rather than an
endocrine component.86
In 80 Saudi patients with sickle cell
anaemia, hormonal assay showed normal
levels of T3, T4 and growth hormone, low
levels of cortisol, testosterone and LH, and
variable changes in FSH.87 These abnorm-
alities occurred more frequently in the
patients with severe disease. Studies of
thyroid function have shown that blood
levels of thyroxine, thyroxine-binding capa-
city and the free thyroxine index were not
significantly different in 90 SS children (1–
15 yrs) than in AS and AA controls.88
Interest in growth hormone dysfunction has
motivated a series of studies by Soliman and
co-workers who demonstrated abnormal-
ities in the growth hormone (GH)/insulin-
like growth factor-I (IGF-I) axis.54,89–92 In
a study of 21 pre-pubertal SS children
with poor growth (height ,10th centile),
defective GH secretion and low insulin-like
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IGF-1 and IGF binding-protein-3 were
demonstrated in 43%, with a reduced
response of IGF-1 production to GH injec-
tion. The disease severity score was signifi-
cantly higher in the group with defective GH
secretion than in the group with normal GH
secretion. The authors presumed there was
partial resistance to GH and that these were
major causes of slow growth, especially in
individuals with severe SCD.80 Although
reduced elements of the GH/IGF-1 axis in
SS children have been found, growth
velocity shows poor correlation with endo-
crine assessment of the axis or thyroid
function.93 Other investigators have
reported a significant correlation between
IGF-1 and height velocity in a sub-group of
sicklers with height ,25th centile.94 In an
analysis of different b globulin haplotypes,
the CAR/CAR haplotype has shown signifi-
cantly lower mean growth velocity and
reduced concentration of IGF-1 compared
with BEN/BEN haplotype, leading to the
conclusion that delay of growth in SCD was
linked to intrinsic factors and disease sever-
ity.93 In a small study of five SCD children
with GH deficiency who received GH
therapy for >3 years, height Z-scores
improved significantly.95
The normal pituitary response to stimula-
tion tests and the conflicting results of
hormonal assessment make it difficult to
evaluate the role of endocrinal dysfunction
in the pathogenesis of growth impairment.
Endocrine function is altered in some
children with SCD, and hormonal therapy
such as GH or IGF-1 might offer therapeu-
tic options.
Micronutrient deficiency
Micronutrient deficiency could be an
important contributor to growth impair-
ment in SCD. In an American study of
170 children (aged 2–12 years) with SCD,
22% were ,5th centile in height and/or
weight,96 and the serum levels of zinc,
retinol, pre-albumin and retinol binding
protein were significantly lower in the 40
cases (who were either growth-retarded or
normal) than in controls. Despite an ade-
quate dietary intake of energy, protein, zinc
and vitamin A, these children with SCD
were leaner and lighter with lower red
blood-cell zinc and serum vitamin A con-
centrations, and higher resting energy
expenditure than controls.97 These findings
were reflected in a survey of 61 American SS
patients and their families on nutrition
knowledge and practice. Overall, 90% of
participants were familiar with the different
food groups but most failed to consume an
appropriate amount of different food
groups, and 59% had incomes below the
poverty level. The authors concluded that
inadequate intake of nutrients was contri-
buting to poor child growth in lower socio-
economic families.98 A recent study evalu-
ated dietary intake by 24-hour recall over
four annual visits in 97 American children
with homozygous SCD and reported a sub-
optimal intake of many nutrients across all
ages, including vitamins D and E, folate,
calcium, magnesium and zinc, with a trend
towards poor diet with increasing age,
particularly during adolescence.99
Folic acid was the first micronutrient
deficiency to be associated with SCD and
has been reported frequently.100–103 Folate
deficiency and megaloblastic erythropoiesis
were observed in about 10% of patients in
Nigeria, and therapeutic administration of
folic acid resulted in improved height and
weight as well as correction of haematologi-
cal changes.104 Other investigators have
failed to demonstrate a correlation between
growth retardation and folate deficiency
as folate supplementation produced no
change in haematological or growth para-
meters.105–108 Routine supplementation in
SCD has been questioned, particularly in
developed countries where folate require-
ments could be provided by a fortified food
intake.109 Vitamin B6 (pyridoxine) defi-
ciency in adults with SCD has also been
reported.110 In children, assessment of
vitamin B6 status by determination of serum
concentrations of pyridoxal 5-phosphate
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(PLP) (the major co-enzyme of vitamin B6)
showed that 77% were below the reference
cut-off, and there were significant positive
associations between PLP levels and BMI
Z-scores, weight and MUAC.111 Reduced
levels of other B vitamins including B12
112
and riboflavin113 have been reported. Folic
acid and vitamins B6 and B12 are important
co-factors in metabolism of the sulphur-
containing amino acid homocysteine, and
deficiencies can lead to hyperhomocystein-
aemia. In the general population, raised
homocysteine concentrations are linked to
increased risk of cardiovascular disease and
stroke.114 Plasma homocysteine is reported
to be elevated in adults115 and chil-
dren116,117 with SCD and significantly so
when complicated by stroke.118 Homo-
cysteine levels can be lowered by supple-
mentation with folic acid or vitamins B6 and
B12. In addition to the maintenance of
effective erythropoiesis, these micronutri-
ents can prevent tissue accumulation of
homocysteine, thus reducing the risk of
endothelial damage and thrombosis.119–121
Serum vitamin A status was reported as
marginal in 66% of American children with
SCD and deficient in 17%. BMI Z-scores
were low, and there were higher rates of
hospital admission of vitamin A-deficient
patients than of those with normal levels.122
Zinc deficiency in SCD occurs at levels
suggesting chronic zinc depletion and
appears to be associated with chronic
haemolysis and hyperzincuria.123 Growth
retardation and hypogonadism were
observed in zinc-depleted men, suggesting
its contribution to impaired growth and
sexual maturation in SCD.81,124 In 104
American children (0.4–18 yrs), low plasma
zinc was reported in 44% of SS cases and,
compared with SS cases with normal plasma
zinc, was associated with impairment of
height, weight, FFM, skeletal growth and
sexual and skeletal maturation.125 Supple-
ments of elemental zinc (10 mg/day) given
for 12 months to 20 children with SCD led
to improved rates of linear growth but there
was no effect on BMI.126
Iron deficiency might not be associated
with SCD owing to the availability of iron
from red cell destruction and increased
intestinal iron absorption in response to
chronic anaemia.127 Even so, patients
receiving sporadic transfusions do not
acquire excessive iron burden during the
1st 2 decades of life.128 Iron deficiency in
SCD is common,129 particularly among
children living in developing countries
where iron deficiency anaemia is highly
prevalent.130 Depletion of iron storage
diagnosed by bone marrow examination
was reported in a high proportion of
SCD children (36–50%) in India and
Nigeria.131–133 Iron deficiency was reported
in 16% of non-transfused American chil-
dren diagnosed by their response to iron
therapy.134 This contrasted with a study of
104 non-transfused patients who showed no
haematological or biochemical evidence of
iron deficiency.135 A study of Jamaican
children followed from birth to 5 years
reported low serum iron in patients and
controls by 1 year of age, but levels sub-
sequently became normal.136 However, a
recent cross-sectional study of 141 Jamaican
SCD children (1–5 yrs) which used several
measurements to determine iron status
showed that 8.5% of cases were iron-
deficient.137 Although the exact mechanism
of iron deficiency in SCD is not clear, the
most probable cause is excessive urinary loss
secondary to chronic haemolysis.138
Iron deficiency in SCD might be bene-
ficial and possibly ameliorate sickling by
decreasing MCHC, which reduces haemo-
lysis, thus prolonging red-cell life-
span139,140 and reducing painful crises141
(which can be precipitated by iron ther-
apy).142 Evidence for the clinical benefits of
iron deficiency is minimal and is limited
because of difficulties in assessing disease
severity.143 Iron deficiency is associated with
growth and intellectual impairment144 and,
in a growing child with SCD, iron require-
ments are increased. Iron-deficient children
are at risk of both growth and neurocogni-
tive impairment imposed by the disease and
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compounded by iron deficiency. These
consequences should be considered before
iron supplementation is withheld.
Vitamin E deficiency occurs in SCD,145
with a high prevalence in children in
developing countries.146,147 Vitamin E has
anti-oxidant properties that could protect
red cells against oxidative stress and its
administration leads to a decrease in the
percentage of irreversibly sickled cells,
which might alleviate symptoms.148
Deficiency of vitamins C149 and D150 and
of minerals such as magnesium151 and
selenium152 has been reported, although
the exact pathophysiological consequences
and contribution to growth delay in SCD
are unclear. The potential benefits of
individual nutrient or multi-micronutrient
supplementation remain to be established.
Food substances with anti-oxidant activ-
ity, which might protect red cell membranes
from oxidative injury, have been used to
treat SCD.153,154 In a small pilot study, oral
administration of dietary omega-3 fatty acid,
provided as menhaden fish oil containing
docosahexanoic acid and eicosapentanoic
acid, produced significant reduction in the
mean number of painful crises, blood
coagulability and platelet adhesion molecule
expression.155 Omega-3 fatty acids are
important components of red cell mem-
branes and their blood levels have been
correlated with indices of disease severity
and haemoglobin concentration in steady-
state SCD. This suggests that there are
clinical benefits through protection against
haemolysis and reduction in vaso-occlusive
episodes or ischaemic organ damage.156 L-
arginine is the natural amino acid substrate
for the synthesis of nitric oxide, a potent
vasodilator that is deficient during sickle cell
crises. When administered orally at a dose of
0.1 g/kg three times a day, it led to a
significant reduction in pulmonary artery
systolic pressure in SCD patients with
pulmonary hypertension.157 This is consis-
tent with vaso-constriction being a signifi-
cant contributor to vaso-occlusion.158 Oral
supplementation of magnesium pidolate
(540 mg/kg/d) has been used to elevate
erythrocyte magnesium and prevent potas-
sium loss by inhibition of the K-Cl co-
transport system, resulting in improved
sickle red-cell hydration and a decrease in
the median number of painful days during a
6-month period of magnesium therapy.159
Several micronutrient deficiencies have
been reported in patients with SCD. Folic
acid is widely administered, usually daily, to
children with SCD, although the optimal
dose is unclear, which relates to uncertainty
concerning the daily requirement. Other
nutrients such as zinc, glutamine, l-arginine
and anti-oxidants might have therapeutic
benefits, and their clinical efficacy needs to
be determined.
Future Perspectives
Under-nutrition relates to increased mor-
bidity and mortality in all children, and
contributes to poor clinical outcome and
severity of disease in children with SCD.
Despite major advances in understanding
the molecular and genetic basis for SCD,
there has been little progress towards
lessening the obvious nutritional problems
faced by these children.160 There has been
limited evaluation of a variety of nutritional
interventions that could influence the nat-
ural history of SCD.161 Improving the
nutritional status and growth of these
children could have a favourable impact on
their clinical course and prognosis. Evalua-
tion of a comprehensive clinical care pro-
gramme in a sub-Saharan Africa setting
produced encouraging results and showed
that improved growth and reduced disease
severity can be attained.162 There are good
opportunities for such programmes with the
introduction of neonatal screening, the
identification of children with SCD at birth
and early interventions using essential
health packages.
Growth monitoring with appropriate
nutritional support as part of the compre-
hensive care of children with SCD should be
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promoted. If the types of nutritional defi-
ciency are known, then clear nutritional
advice and care can be given by health
workers to children and their families. This
allows the identification of children who do
not adhere to nutritional interventions and
of high-risk cases. It might facilitate the use
of alternative interventions including drugs,
hormones or other treatments in specific
cases.
Small stature and delayed sexual maturity
can carry long-term psychological conse-
quences that affect the ability of the
adolescent with SCD to form normal
relationships with the opposite sex, leading
to low self-esteem and depression.163
Growth retardation has been associated with
impaired mental development and a low
intelligence quotient,164 and nutritional
interventions with their potential for
improving long-term growth and develop-
ment could improve prognosis, particularly
if commenced in early childhood before
growth retardation becomes established.
These interventions might lead to reduction
in the severity of crises and vascular com-
plications, or episodes of vasoconstriction.
There is little information on the influ-
ence of several important genetic poly-
morphisms on nutritional status in SCD.
For example, methylene-tetrahydrofolate
reductase deficiency, which is not infre-
quent in subjects with SCD,165–168 would
influence host folate status and homocys-
teine metabolism with possible effects on
sickle cell vasculopathy. Similarly, glucose-
6-phosphate dehydrogenase deficiency
could affect severity of haemolysis in sickle
cell anaemia, although some studies of
this genotype have shown little additive
effect.169 Pooled data from studies of
different haplotype profiles need to be
interpreted carefully, taking these various
factors into consideration.
In order to assess the benefits for child
growth and the reduction of disease severity,
randomised trials of nutritional interven-
tions in infancy and early childhood com-
bined with appropriate health care packages
are required. There are few studies from
Africa and the Arabian Peninsula and
increased efforts are required to address
this disparity, particularly in low-resource
settings.
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